Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 513 matching trials from the live ClinicalTrials.gov search.
Conditions
Myeloid Chimerism
Interventions
CliniMACS CD34 Reagent
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2037
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Myeloma
Interventions
G-CSF, Plerixafor, Apheresis, Melphalan, Stem cell re-infusion, Basiliximab, CliniMACS CD25 microbeads and cell sorter
Drug · Procedure · Device
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Busulfan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Emapalumab, Fludarabine, Hematopoietic Cell Transplantation, Melphalan, Multigated Acquisition Scan, Mycophenolate Mofetil, Questionnaire Administration, Tacrolimus
Procedure · Drug · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Post Hematopoietic Stem Cell Transplantation
Interventions
Data Collection
Other
Lead sponsor
Karen Wood
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts
Interventions
Dilanubicel, Cyclophosphamide, Fludarabine, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation, Laboratory Biomarker Analysis, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Multigated Acquisition Scan, Electrocardiography, Computed Tomography
Biological · Drug · Radiation + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
10 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions
G-CSF plus plerixafor, rituximab
Drug · Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Obesity, Malignant Neoplasm
Interventions
Interview, Media Intervention, Questionnaire Administration, Scale Device, Telephone-Based Intervention, Text Message
Other · Behavioral
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
13 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Multiple Myeloma
Interventions
myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D
Device · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Blood Draw
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Breast Carcinoma Metastatic to the Bone, Stage IV Breast Cancer
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
20 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Multiple Myeloma
Interventions
Structural Image, Functional Image, Digit Span subtest, Brief Test of Attention, Trail Making Test (Parts A & B), Auditory Consonant Trigrams Test, Controlled Oral Word Association Test, Hopkins Verbal Learning Test-Revised, The Center for Epidemiological Study-Depression, The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4, Blood draw
Diagnostic Test · Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Conditions
Esophageal Cancer
Interventions
Tumor Biopsy via Ultrasound Endoscopy
Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Miami, Florida
Conditions
Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide, bortezomib, thalidomide, melphalan, autologous stem cell transplant
Drug · Procedure
Lead sponsor
Margarida Magalhaes-Silverman
Other
Eligibility
65 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Testicular Germ Cell Tumor
Interventions
DNA analysis, polymerase chain reaction, flow cytometry, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Leukemia, Childhood Acute Leukemia of Ambiguous Lineage, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography, Electronic Health Record Review, Quality-of-Life Assessment, Questionnaire Administration, Revumenib
Procedure · Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
2 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Conditions
Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease
Interventions
G-CSF plus Plerixafor
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
No Longer Available No phase listed Expanded access

CliniMACS® CD34+ Reagent System for Expanded Access Use

NCT02026934
Conditions
Graft-Versus-Host Disease(GVHD), Anemia Due to Disturbance of Proliferation and/or Differentiation of Hematopoietic Stem Cells, Graft Failure, Delayed Graft Function
Interventions
CliniMACS CD34 Reagent System
Device
Lead sponsor
Joseph Antin
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Non-Hodgkin's Lymphoma
Interventions
Granulocyte-colony stimulating factor (G-CSF), Fixed Dose Plerixafor, Weight-Based Plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 78 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Duarte, California • Aurora, Colorado
Conditions
Breast Cancer, Lymphoma
Interventions
questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, therapeutic autologous lymphocytes, cyclophosphamide, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Tandem autologous stem cell transplant, Cisplatin, Doxorubicin, Cyclophosphamide, Etoposide, Bortezomib, Thalidomide, Melphalan
Drug · Procedure
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Shwachman-Diamond Syndrome, Hematologic Neoplasm With Germline GATA2 Mutation, Hematologic Neoplasm With Germline SAMD9 Mutation, Hematologic Neoplasm With Germline SAMD9L Mutation
Interventions
Treosulfan, Fludarabine Phosphate, Tacrolimus, Methotrexate, Lapine T-Lymphocyte Immune Globulin, Peripheral Blood Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Quality-of-Life Assessment, Echocardiography, Multigated Acquisition Scan, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, X-Ray Imaging, Computed Tomography
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 49 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 20 more
Conditions
Lymphoma, B-cell Lymphoma
Interventions
Leukapheresis, Stem Cell Transplant, CD19-specific T Cell Infusion, IL-2, Carmustine, Etoposide, Cytarabine, Melphalan
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab, Gemcitabine, Oxaliplatin, Positron Emission Tomography, Rituximab
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Duarte, California • Newnan, Georgia • Zion, Illinois